Ozempic and Wegovy have more in common than most people assume. Both contain semaglutide, the same active molecule, and both are given as a once-weekly injection. The chemistry inside the two pens is identical, and so is the rhythm of taking them.
The rules around them are not. The approvals are different, the dose ladders are different, and the guidance for a missed dose points in different directions depending on which box the pen came from. This article lines the two up plainly. It deliberately does not compare results or argue that one is better; that question belongs to you and your prescriber, and we have no business answering it.
One molecule, two brand names
A single medication molecule can be approved more than once, for different uses, under different brand names. Semaglutide is a working example of how far that can go. It exists as a weekly injection under two brand names and as a daily tablet under a third, and each approval carries its own prescribing information, written for the use it was approved for.
In this pair, the split is clean. Ozempic is approved for type 2 diabetes. Wegovy is approved for long-term weight management. Those approved uses, sometimes called indications, are the root of nearly every practical difference between the two: who tends to be prescribed which, what a pharmacy benefit asks before it pays, and which dose ladder the prescription climbs.
None of this changes what is in the pen. Both are weekly subcutaneous injections of the same molecule, and both build up and ease off inside the body on the same roughly week-long timeline.
Why the approved use drives the paperwork
Coverage is organized around the approved use, not the molecule. A medication approved for type 2 diabetes is typically reviewed under a different set of criteria than one approved for long-term weight management, which means two people taking identical semaglutide doses can have completely different authorization experiences purely because their prescriptions carry different brand names.
The paperwork that follows, prior authorizations, appeals, documentation of the treatment schedule, tends to ask for the same raw material no matter which brand is involved: what you were prescribed, when you actually took it, and how the treatment has gone. That is one place a dose log quietly earns its keep, and we wrote a separate guide on prior authorizations and how your dose log helps the paperwork.
The brand name also follows you into the pharmacy record. Refill histories, substitution rules and coverage determinations all attach to the product that was dispensed, which is one more quiet reason to log what you actually take rather than the molecule it contains.
Which of the two makes sense for a given person is a prescriber decision, made with the whole health picture in view: history, other conditions, insurance, and how the treatment is going. It is not a question an article or an app should weigh in on, and we will not.
The two ladders side by side
Both medications climb rather than start at full strength, but they climb different numbers of rungs. Ozempic moves through four strengths, and its maintenance doses top out at 2 mg weekly. Wegovy moves through five to 2.4 mg weekly, and its label allows one step beyond that for weight reduction in adults. On Ozempic, the steps are typically spaced four weeks apart, and the lowest strength, 0.25 mg, is a starting dose rather than a maintenance dose; its job is to introduce the body to the medication.
Here is the pair in one place, strength by strength:
| Step | Ozempic (mg) | Wegovy (mg) |
|---|---|---|
| Starting step | 0.25 | 0.25 |
| Second step | 0.5 | 0.5 |
| Third step | 1.0 | 1.0 |
| Fourth step | 2.0 | 1.7 |
| Fifth step | no fifth step | 2.4 |
A few things are worth noticing in that table. The first three rungs are identical, which is why the early months of either treatment can look so similar in a log. The ladders then part ways: Ozempic's fourth step is its ceiling, while Wegovy keeps climbing through 1.7 mg to 2.4 mg, and, for weight reduction in adults, past it. And nobody is required to reach the top of either ladder. Where a person settles is a tolerance question and a prescriber decision, not a finish line.
The reasoning behind ladders in general, why these medications start low and climb slowly, has its own article in our guide to GLP-1 titration schedules explained.
GLP 1 Tracker AppOzempic and Wegovy presets with their real ladders, so your log always knows which rules apply. Free and private.
Get the app
The missed dose rules differ
This is where the two rule sets genuinely part company, and it catches out anyone who thinks of the pens as interchangeable. Per the prescribing information:
- Ozempic. If you miss a dose, the window is 5 days: take it as soon as possible within 5 days, then return to your usual schedule.
- Wegovy. The rule turns on the calendar. Take the missed dose as soon as possible if your next scheduled dose is more than 2 days away. If it is less than 2 days away, skip the missed dose entirely.
- Wegovy, after repeated misses. After two or more missed doses in a row, the label says to call your prescriber, who may restart the ladder.
One rule is shared: never take a double dose. A missed week never justifies two doses at once, on either brand.
These windows make sense once you know how long semaglutide lingers, but the short version is that the labels already did that math, so you do not have to. Our summary of what the official guidance says about a missed GLP-1 dose collects the exact rules for every medication in the class, including both of these.
Where the rule books agree
For all the differences above, the shared molecule keeps showing through. Both are weekly injections with the same basics: subcutaneous, into the abdomen, front of the thigh or upper arm, with sites rotated, a habit with its own article on injection site rotation. Both carry the same minimum gap of 48 hours if you ever need to move your shot day. And because both are semaglutide, both follow the same roughly week-long half-life, building toward a steady level over about a month, which is the subject of our article on semaglutide's half-life and your medication level.
The labeled side effect picture is shared as well, since it comes from the molecule rather than the brand: gastrointestinal effects such as nausea are the most common, typically worst after starting and after dose increases, and tending to ease over weeks. Reading your own symptoms against the step you just took, rather than against the brand name, is usually the more useful comparison.
One practical place the rule books part ways again is the room-temperature clock. Commonly published storage figures allow Ozempic in use for up to 56 days at or below 30 C once it leaves refrigeration, and Wegovy single-dose pens for up to 28 days, so check your product's label rather than carrying one figure between the two. Writing down when a pen entered service makes that clock easy to keep.
Why your log should name the brand
Write down semaglutide 1.0 mg and you have recorded a true fact that leaves out the most useful information. Which ladder are you on? Which missed dose window applies to you? Is there a step above you or not? The brand name answers all three at once.
That is why tracking apps built for this class keep the two as separate presets with their own ladders. In GLP 1 Tracker App, picking the brand gives you the correct rungs to tap when you log a dose, automatic week counts at each step, shot day reminders and overdue alerts, and an educational curve of how your medication level builds between doses. A short note attaches to any dose entry, which is the right home for details like the injection site you used.
If your prescription ever moves from one brand to the other, that is a prescriber conversation, full stop. The same molecule does not make the two interchangeable in the eyes of an insurer or a pharmacy record, and the transition has its own mechanics, which we cover in switching GLP-1 medications and tracking through the transition. And if you arrived here wondering about the tablet form of semaglutide, that is a third product with its own rules entirely: Rybelsus, the daily oral semaglutide.
The takeaway
Ozempic and Wegovy are the same molecule, semaglutide, taken as the same weekly injection. Almost everything written around them differs. Ozempic is approved for type 2 diabetes and climbs four steps to a 2 mg ceiling; Wegovy is approved for long-term weight management and climbs five steps to 2.4 mg, with one further step available for weight reduction in adults. Miss an Ozempic dose and the window is 5 days; miss a Wegovy dose and the rule turns on whether your next dose is more than 2 days away, with a call to the prescriber after two misses. None of it changes the chemistry. All of it changes the paperwork, the ladder under your feet, and the entry that belongs in your log: the brand, not just the molecule.
Log the brand, not just the moleculeBoth ladders built in, week counts automatic, every dose on your phone and nowhere else.
Download
Frequently asked questions
What is the difference between Ozempic and Wegovy?
The active ingredient is the same: both contain semaglutide, given as a once-weekly injection. The difference is the approval. Ozempic is approved for type 2 diabetes, and Wegovy is approved for long-term weight management. That difference drives the dose ladders, the missed dose rules and much of the insurance paperwork around each prescription.
Do Ozempic and Wegovy have the same doses?
They share their first three steps and then part ways. Both start at 0.25 mg and climb through 0.5 and 1.0 mg. Ozempic then steps to 2.0 mg, which is its highest maintenance dose. Wegovy instead steps to 1.7 mg and then 2.4 mg, its recommended maintenance dose, and for weight reduction in adults the label allows a further step to 7.2 mg after at least four weeks at 2.4 mg. On Ozempic the 0.25 mg strength is a starting dose rather than a maintenance dose, and steps are typically spaced four weeks apart.
Are the missed dose rules different for Ozempic and Wegovy?
Yes, and this surprises people who treat the two as interchangeable. Per the prescribing information, a missed Ozempic dose can be taken within 5 days. For Wegovy, the rule depends on timing: take it as soon as possible if the next scheduled dose is more than 2 days away, and skip it if it is not. After two or more missed Wegovy doses, the label says to call your prescriber, who may restart the ladder. Never take a double dose of either.
Can I switch from Ozempic to Wegovy on my own?
No. Even though both contain the same molecule, a change between them is a prescriber conversation, because the approvals, the dose ladders and the insurance rules differ. Your prescriber decides what the prescription should say and how to handle the transition. What you can do is keep a clean record of every dose, so the conversation starts from facts rather than memory.
Is Rybelsus the same as Ozempic and Wegovy?
Rybelsus contains the same active molecule, semaglutide, but it is a daily tablet rather than a weekly injection, and its rules are entirely its own: it is taken on an empty stomach with plain water, with a wait before food, drink or other oral medications. It climbs its own ladder of 3, 7 and 14 mg. So same molecule, different product, different rulebook.